Antiviral effect of Evusheld in COVID-19 hospitalized patients infected with pre-Omicron or Omicron variants: a modelling analysis of the randomized DisCoVeRy trial
Journal of Antimicrobial Chemotherapy · 2024
DOI: 10.1093/jac/dkae301 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Maxime Beaulieu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris Cité et Université Sorbonne Paris Nord, Inserm, IAME, F-75018 Paris, France. Hauptthemen laut MEDLINE: SARS-CoV-2, Antiviral Agents, COVID-19, COVID-19 Drug Treatment. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: European Commission, DIM One Health Île-de-France, AstraZeneca.
Abstract (Originalsprache)
Background
The antiviral efficacy of Evusheld (AZD7442) in patients hospitalized for SARS-CoV-2 is unknown.
Methods
We analysed the evolution of both the nasopharyngeal viral load and the serum neutralization activity against the variant of infection in 199 hospitalized patients (109 treated with Evusheld, 90 treated with placebo) infected with the SARS-CoV-2 virus and included in the randomized, double-blind, trial DisCoVeRy (NCT04315948). Using a mechanistic mathematical model, we reconstructed the trajectories of viral kinetics and how they are modulated by the increase in serum neutralization activity during Evusheld treatment.
Results
Our model identified that the neutralization activity was associated with viral kinetics. Reflecting the variant-dependent neutralization activity of Evusheld, the antiviral activity of Evusheld was larger in patients infected with pre-Omicron or Omicron BA.2 variants than in patients infected with Omicron BA.1 variant. More specifically, the model predicted that Evusheld reduced the median time to viral clearance compared with placebo-treated patients by more than 5 days in patients infected by pre-Omicron (median: 5.9; 80% PI: 2.1–13.6) or Omicron BA.2 (median: 5.4; 80% PI: 2.0–12.4), respectively. The effect was more modest in patients infected by the Omicron BA.1 variant, reducing the median time to viral clearance by 2 days (median: 2.2; 80% PI: 0.4–8.9).
Conclusions
Hospitalized patients treated with Evusheld had a shorter median time to SARS-CoV-2 viral clearance. As Evusheld antiviral activity is mediated by the level of neutralization activity, its impact on viral clearance varies largely according to the variant of infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Université Paris Cité et Université Sorbonne Paris Nord, Inserm, IAME, F-75018 Paris, France.
- Hospices Civils de Lyon, Laboratoire de Virologie, Institut des Agents Infectieux de Lyon, Centre National de Référence des virus respiratoires France Sud, F-69317 Lyon, France.
- Université Claude Bernard Lyon 1, Virpath, CIRI, INSERM U1111, CNRS UMR5308, ENS Lyon, F69372 Lyon, France.
- Département d'Épidémiologie, Biostatistique et Recherche Clinique, AP-HP, Hôpital Bichat, F75018 Paris, France.
- AP-HP, Hôpital Bichat, Service de Maladies Infectieuses et Tropicales, F-75018 Paris, France.
- National Institute for Health Research, Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, London, UK.
ORCID-Profile: Maxime Beaulieu, Alexandre Gaymard, Nathan Peiffer-Smadja, Guillaume Lingas, France Mentré, Florence Ader, Maya Hites, Pascal Poignard, Jérémie Guedj
Förderung
- European Commission
- DIM One Health Île-de-France
- AstraZeneca
Zitieren
APA
Beaulieu, M., Gaymard, A., Massonnaud, C., Peiffer-Smadja, N., Bouscambert-Duchamp, M., Carcelain, G., Lingas, G., Mentré, F., Ader, F., Hites, M., Poignard, P., & Guedj, J. (2024). Antiviral effect of Evusheld in COVID-19 hospitalized patients infected with pre-Omicron or Omicron variants: a modelling analysis of the randomized DisCoVeRy trial. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae301
Vancouver
Beaulieu M, Gaymard A, Massonnaud C, Peiffer-Smadja N, Bouscambert-Duchamp M, Carcelain G, et al. Antiviral effect of Evusheld in COVID-19 hospitalized patients infected with pre-Omicron or Omicron variants: a modelling analysis of the randomized DisCoVeRy trial. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae301
BibTeX
@article{Beaulieu2024,
author = {Beaulieu, Maxime and Gaymard, Alexandre and Massonnaud, Clément and Peiffer-Smadja, Nathan and Bouscambert-Duchamp, Maude and Carcelain, Guislaine and Lingas, Guillaume and Mentré, France and Ader, Florence and Hites, Maya and Poignard, Pascal and Guedj, Jérémie},
title = {Antiviral effect of Evusheld in COVID-19 hospitalized patients infected with pre-Omicron or Omicron variants: a modelling analysis of the randomized DisCoVeRy trial},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2024},
doi = {10.1093/jac/dkae301}
}
EUVIMED